Table 1 Basic characteristics of included studies
Reference | Trial | Study phase | Stage | Treatment line | PD-1/PD-L1 (n) | Control (n) | Primary endpoint | Median (range) Age (years) | Males (%) | Tumor site | ECOG | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PD-1/ PD-L1 | Control | PD-1/ PD-L1 | Control | GC (%) | GEJC (%) | PD-1/ PD-L1 | Control | ||||||||||||
PD-1/ PD-L1 | Control | PD-1/ PD-L1 | Control | 0 (%) | 1 (%) | 0 (%) | 1 (%) | ||||||||||||
Bang et al. 2018 [40] | JAVELIN Gastric 300 | III | Advanced | 3L | Avelumab (185) | Physician’s choice of chemotherapy (186) | OS | 59 (29–86) | 61 (18–82) | 75.7 | 68.3 | 65.9 | 74.2 | 34.1 | 25.8 | 35.7 | 64.3 | 33.3 | 66.7 |
Shitara et al. 2018 [41] | KEYNOTE-061 | III | Advanced |  ≥ 2L | Pembrolizumab (196) | Chemotherapy (199) | OS and PFS | 64 (57–70) | 61 (54–68) | 74 | 70 | 68 | 63 | 32 | 37 | 45 | 55 | 46 | 53 |
Shitara et al. 2020 Arm A [42] | KEYNOTE-062 | III | Advanced | 1L | Pembrolizumab (256) | Chemotherapy (250) | OS and PFS | 61.0 (20–83) | 62.5 (23–87) | 70.3 | 71.6 | 68.8 | 72.4 | 30.9 | 26.8 | 51.2 | 48.8 | 46.0 | 54.0 |
Shitara et al. 2020 Arm B [42] | Pembrolizumab + Chemotherapy (257) | 62.0 (22–83) | 62.5 (23–87) | 75.9 | 71.6 | 66.1 | 72.4 | 33.1 | 26.8 | 46.3 | 53.7 | 46.0 | 54.0 | ||||||
Kang et al. 2022 [43] | ATTRACTION-4 | III | Advanced or recurrent | 1L | Nivolumab + Chemotherapy (362) | Placebo + Chemotherapy (362) | PFS and OS | 64 (25–86) | 65 (27–89) | 70 | 75 | 65 | 66 | 8 | 9 | 54 | 46 | 54 | 46 |